Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis

Free Radical Biology and Medicine

Volumn 47, Issue 6, 2009, Pages 779-785

  Thotala, Dinesh ^a   Chetyrkin, Sergei ^a   Hudson, Billy ^a,b,c   Hallahan, Dennis ^a,b,c   Voziyan, Paul ^a,b   Yazlovitskaya, Eugenia ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Apoptosis; Free radicals; Gastrointestinal tract; Ionizing radiation; Pyridoxamine; Radiation toxicity; Radioprotection; Reactive carbonyl species; Reactive oxygen species

Indexed keywords

AMIFOSTINE; CARBONYL DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; INTESTINE EPITHELIUM; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; RAT; WHOLE BODY RADIATION;

AMIFOSTINE; ANIMALS; APOPTOSIS; CELL LINE; CYTOPROTECTION; FREE RADICAL SCAVENGERS; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; PYRIDOXAMINE; RADIATION INJURIES, EXPERIMENTAL; RADIATION, IONIZING; RADIATION-PROTECTIVE AGENTS;

ANIMALIA;

EID: 68349128509     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.06.020     Document Type: Article

References (48)

1. Halliwell B., and Gutteridge J.M.C. Free Radicals in Biology and Medicine (1999), Oxford Univ. Press, London
2. Stadtman E.R. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu. Rev. Biochem. 62 (1993) 797-821
3. Fan X. Ionizing radiation induces formation of malondialdehyde, formaldehyde, and acetaldehyde from carbohydrates and organic acid. J. Agric. Food Chem. 51 (2003) 5946-5949
4. Potten C.S.A. comprehensive study of the radiobiological response of the murine (BDF1) small intestine. Int. J. Radiat. Biol. 58 (1990) 925-973
5. Withers H.R. Regeneration of intestinal mucosa after irradiation. Cancer 28 (1971) 75-81
6. Bowen J.M., Gibson R.J., Cummins A.G., and Keefe D.M. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 14 (2006) 713-731
7. Goldman M. The Russian radiation legacy: its integrated impact and lessons. Environ. Health Perspect. 105 Suppl. 6 (1997) 1385-1391
8. Ramachandran A., Madesh M., and Balasubramanian K.A. Apoptosis in the intestinal epithelium: its relevance in normal and pathophysiological conditions. J. Gastroenterol. Hepatol. 15 (2000) 109-120
9. Potten C.S. Extreme sensitivity of some intestinal crypt cells to X and gamma irradiation. Nature 269 (1977) 518-521
10. Vijayalaxmi, Reiter R.J., Tan D.X., Herman T.S., and Thomas Jr. C.R. Melatonin as a radioprotective agent: a review. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 639-653
11. Petrovecki M., Prager A., Terry N.H., Murray D., and Relationships between D.N.A. damage and the survival of murine bone marrow cells irradiated in situ. Radiat. Res. 138 (1994) 443-450
12. Weiss J.F., and Landauer M.R. Radioprotection by antioxidants. Ann. N. Y. Acad. Sci. 899 (2000) 44-60
13. Maisin J.R. Chemical radioprotection: past, present, and future prospects. Int. J. Radiat. Biol. 73 (1998) 443-450
14. Voziyan P.A., and Hudson B.G. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol. Life Sci. 62 (2005) 1671-1681
15. Zheng F., Zeng Y.J., Plati A.R., Elliot S.J., Berho M., Potier M., Striker L.J., and Striker G.E. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int. 70 (2006) 507-514
16. Degenhardt T.P., Alderson N.L., Arrington D.D., Beattie R.J., Basgen J.M., Steffes M.W., Thorpe S.R., and Baynes J.W. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61 (2002) 939-950
17. Stitt A., Gardiner T.A., Alderson N.L., Canning P., Frizzell N., Duffy N., Boyle C., Januszewski A.S., Chachich M., Baynes J.W., and Thorpe S.R. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51 (2002) 2826-2832
18. Williams M.E., Bolton W.K., Khalifah R.G., Degenhardt T.P., Schotzinger R.J., and McGill J.B. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27 (2007) 605-614
19. Williams M.E. New potential agents in treating diabetic kidney disease: the fourth act. Drugs 66 (2006) 2287-2298
20. Voziyan P.A., Metz T.O., Baynes J.W., and Hudson B.G.A. post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277 (2002) 3397-3403
21. Nagaraj R.H., Sarkar P., Mally A., Biemel K.M., Lederer M.O., and Padayatti P.S. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 402 (2002) 110-119
22. Amarnath V., Amarnath K., Davies S., and Roberts II L.J. Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem. Res. Toxicol. 17 (2004) 410-415
23. Chetyrkin S.V., Zhang W., Hudson B.G., Serianni A.S., and Voziyan P.A. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 47 (2008) 997-1006
24. Onorato J.M., Jenkins A.J., Thorpe S.R., and Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions: mechanism of action of pyridoxamine. J. Biol. Chem. 275 (2000) 21177-21184
25. Chetyrkin S.V., Mathis M.E., Ham A.J., Hachey D.L., Hudson B.G., and Voziyan P.A. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Free Radic. Biol. Med. 44 (2008) 1276-1285
26. +)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic. Biol. Med. 30 (2001) 232-237
27. Metz T.O., Alderson N.L., Chachich M.E., Thorpe S.R., and Baynes J.W. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J. Biol. Chem. 278 (2003) 42012-42019
28. Halliwell B., and Gutteridge J.M.C. Hydroxyl radicals assayed by aromatic hydroxylation and deoxyribose degradation. In: Greenwald R.A. (Ed). Handbook of Methods for Oxygen Radical Research (1986), CRC Press, Boca Raton, FL 177-180
29. Yazlovitskaya E.M., Edwards E., Thotala D., Fu A., Osusky K.L., Whetsell Jr. W.O., Boone B., Shinohara E.T., and Hallahan D.E. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res. 66 (2006) 11179-11186
30. Tanimoto M., Gohda T., Kaneko S., Hagiwara S., Murakoshi M., Aoki T., Yamada K., Ito T., Matsumoto M., Horikoshi S., and Tomino Y. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56 (2007) 160-167
31. Canning P., Glenn J.V., Hsu D.K., Liu F.T., Gardiner T.A., and Stitt A.W. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp. Diabetes Res. 2007 (2007) 51837
32. Ran X., Cheng T., Shi C., Xu H., Qu J., Yan G., Su Y., Wang W., and Xu R. The effects of total-body irradiation on the survival and skin wound healing of rats with combined radiation-wound injury. J. Trauma 57 (2004) 1087-1093
33. Hosseinimehr S.J. Trends in the development of radioprotective agents. Drug Discov. Today 12 (2007) 794-805
34. Cassatt D.R., Fazenbaker C.A., Bachy C.M., and Hanson M.S. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin. Radiat. Oncol. 12 (2002) 97-102
35. Weiss J.F., and Landauer M.R. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 189 (2003) 1-20
36. Herodin F., and Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp. Hematol. 33 (2005) 1071-1080
37. Voziyan P.A., Khalifah R.G., Thibaudeau C., Yildiz A., Jacob J., Serianni A.S., and Hudson B.G. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 278 (2003) 46616-46624
38. Davies S.S., Brantley E.J., Voziyan P.A., Amarnath V., Zagol-Ikapitte I., Boutaud O., Hudson B.G., Oates J.A., and Ii L.J. Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H(2)O(2)-mediated cytotoxicity. Biochemistry 45 (2006) 15756-15767
39. Thompson M.A. Maintaining a proper perspective of risk associated with radiation exposure. J. Nucl. Med. Technol. 29 (2001) 137-142 quiz 148-150
40. Saenger E.L. Radiation accidents. Ann. Emerg. Med. 15 (1986) 1061-1066
41. Miller K.L. The nuclear reactor accident at Three Mile Island. Radiographics 14 (1994) 215-224
42. Chin F.K. Scenario of a dirty bomb in an urban environment and acute management of radiation poisoning and injuries. Singap. Med. J. 48 (2007) 950-957
43. Rosoff H., and von Winterfeldt D. A risk and economic analysis of dirty bomb attacks on the ports of Los Angeles and Long Beach. Risk Anal. 27 (2007) 533-546
44. Brugge D., deLemos J.L., and Bui C. The Sequoyah Corporation fuels release and the Church Rock spill: unpublicized nuclear releases in American Indian communities. Am. J. Public Health 97 (2007) 1595-1600
45. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 8 (2007) 1007-1017
46. Arlow F.L., Dekovich A.A., Priest R.J., and Beher W.T. Bile acids in radiation-induced diarrhea. South. Med. J. 80 (1987) 1259-1261
47. 14C-lactose breath tests during pelvic radiotherapy: the effect of the amount of small bowel irradiated. Radiology 142 (1982) 507-510
48. Anno G.H., Baum S.J., Withers H.R., and Young R.W. Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. Health Phys. 56 (1989) 821-838